Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): July 2026 to July 2027.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): June 2026 to June 2027.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): May 2026 to May 2027.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): April 2026 to April 2027.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): March 2026 to March 2027.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): February 2026 to February 2027.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): January 2026 to January 2027.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): December 2025 to December 2026.
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): November 2025 to November 2026.
For someone already managing chronic disease, menopause can disrupt stability and complicate treatment plans in ways that aren’t always immediately visible but show up over time in outcomes and utilization. The post Menopause Is an Overlooked Driver of Cost in High-Risk Populations appeared first on MedCity News .
Roche has halted development on two of its Huntington’s disease prospects, marking another blow for a patient community that has long awaited new medicines.
by Silas Ruhrberg Estévez, Dyke Ferber, Mihaela van der Schaar, Jakob Nikolas Kather Medical artificial intelligence research is shifting from single-task models toward multimodal large language model-based agents for complex clinical workflows, requiring benchmarks that assess clinical reasoning, process safety, and resource stewardship rather than final outputs alone. In this Perspective article, Silas Ruhrberg Estévez and colleagues discuss why, as medical AI research shifts toward multimodal large language model-based agents for complex clinical workflows, benchmarks that assess clinical…
by Marie Auzanneau, Resthie R. Putri, Martin Wannack, Pernilla Danielsson, Stephanie Brandt-Heunemann, Claude Marcus, Susann Weihrauch-Blüher, Stefanie Lanzinger, Emilia Hagman Background Whether socioeconomic status (SES) influences obesity treatment response among children remains unclear. This study aimed to examine the association between SES and response to health behavior and lifestyle pediatric obesity treatment over 3 years in two European countries. Methods and findings In this two-cohort study, data were obtained from the Swedish Childhood Obesity Treatment Register (BORIS) and the…
by Daniel Stow, Ruby S. M. Tsang, Ioanna K. Katzourou, Qinqin Huang, Miriam Samuel, Megan L. Wood, Jack F. G. Underwood, Genes and Health Research Team, The LIfespaN multimorbidity research Collaborative (LINC) , Rupert A. Payne, James T. R. Walters, Nicholas J. Timpson, Inês Barroso, Hilary C. Martin, Peter A. Holmans, Marianne B. M. van den Bree, Rohini Mathur, Sarah Finer Background UK South Asian populations are at high risk of physical and mental health multimorbidity, which means they live with multiple long-term conditions. The life course emergence of multimorbidity, its underlying…
“We have all this data that’s available, but it’s actually not actionable because we don’t have a way to get it into clinical workflow,” said American Medical Association CEO Dr. John Whyte.
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
The organizations that move now — with the right foundation and the right partners — will enter the next planning cycle with a specialty pharmacy that functions as a true strategic asset. The post Specialty Pharmacy Is No Longer Optional Infrastructure appeared first on MedCity News .
Non-surgical implantable BCI is increasingly capable of matching surgical performance while transforming the risk-benefit equation, and it is now the most credible path along all three dimensions simultaneously. The post Brain Interfaces Don’t Need Surgery to Be Transformative – and the Distinction Is Now a Strategic One appeared first on MedCity News .